Glenmark Pharmaceuticals has received final approval from the U.S. Food & Drug Administration (U.S. FDA) for its Progesterone Vaginal Inserts, 100 mg. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin. This milestone represents a strategic expansion of Glenmark’s North American portfolio, targeting a market that recorded annual sales of approximately $59.2 million for the 12-month period ending in February 2026.
Strategic Market Expansion
Glenmark Pharmaceuticals has successfully secured U.S. FDA approval for its 100 mg Progesterone Vaginal Inserts. This approval validates the product as both bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin, produced by Ferring Pharmaceuticals. The company plans to leverage its existing commercial infrastructure to distribute the product across the United States, further solidifying its presence in the women’s healthcare segment.
Market Opportunity and Leadership Commentary
Data from IQVIA indicates that the market for 100 mg Progesterone Vaginal Inserts generated approximately $59.2 million in annual sales for the period ending February 2026. This approval provides Glenmark with a significant opportunity to capture market share in a well-established therapeutic space. Commenting on the development, Marc Kikuchi, President & Business Head, North America, stated that the launch aligns with the company’s commitment to expanding access to quality and affordable medicines for patients.
Focus on Women’s Health
The introduction of this product is a key addition to Glenmark’s North American portfolio, reinforcing its strategic focus on specialty healthcare. By providing a high-quality alternative to the existing reference product, the company continues to address critical patient needs in women’s healthcare, a core area of the company’s broader innovation and access strategy.
Source: BSE
